ATE292973T1 - Verwendung eines adenosin-a3-rezeptor-agonisten zur hemmung der virenreplikation - Google Patents

Verwendung eines adenosin-a3-rezeptor-agonisten zur hemmung der virenreplikation

Info

Publication number
ATE292973T1
ATE292973T1 AT02729507T AT02729507T ATE292973T1 AT E292973 T1 ATE292973 T1 AT E292973T1 AT 02729507 T AT02729507 T AT 02729507T AT 02729507 T AT02729507 T AT 02729507T AT E292973 T1 ATE292973 T1 AT E292973T1
Authority
AT
Austria
Prior art keywords
adenosine
cells
receptor agonist
virus replication
inhibit virus
Prior art date
Application number
AT02729507T
Other languages
English (en)
Inventor
Pnina Fishman
Kamel Khalili
Original Assignee
Can Fite Biopharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Can Fite Biopharma Ltd filed Critical Can Fite Biopharma Ltd
Application granted granted Critical
Publication of ATE292973T1 publication Critical patent/ATE292973T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
AT02729507T 2001-01-16 2002-01-13 Verwendung eines adenosin-a3-rezeptor-agonisten zur hemmung der virenreplikation ATE292973T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26165901P 2001-01-16 2001-01-16
PCT/IL2002/000028 WO2002055085A2 (en) 2001-01-16 2002-01-13 Use of an adenosine a3 receptor agonist for inhibition of viral replication

Publications (1)

Publication Number Publication Date
ATE292973T1 true ATE292973T1 (de) 2005-04-15

Family

ID=22994269

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02729507T ATE292973T1 (de) 2001-01-16 2002-01-13 Verwendung eines adenosin-a3-rezeptor-agonisten zur hemmung der virenreplikation

Country Status (12)

Country Link
US (1) US7589075B2 (de)
EP (1) EP1365776B1 (de)
JP (1) JP4012070B2 (de)
CN (1) CN1259056C (de)
AT (1) ATE292973T1 (de)
AU (1) AU2002219497B2 (de)
BR (1) BR0206492A (de)
CA (1) CA2434906C (de)
DE (1) DE60203702T2 (de)
HK (1) HK1064948A1 (de)
IL (1) IL156704A0 (de)
WO (1) WO2002055085A2 (de)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020115635A1 (en) * 2001-02-21 2002-08-22 Pnina Fishman Modulation of GSK-3beta activity and its different uses
US7414036B2 (en) 2002-01-25 2008-08-19 Muscagen Limited Compounds useful as A3 adenosine receptor agonists
AR049384A1 (es) 2004-05-24 2006-07-26 Glaxo Group Ltd Derivados de purina
DK1758596T3 (da) 2004-05-26 2010-07-26 Inotek Pharmaceuticals Corp Purinderivater som adenosin-A1-receptoragonister og fremgangsmåder til anvendelse deraf
US7863253B2 (en) 2004-09-20 2011-01-04 Inotek Pharmaceuticals Corporation Purine Derivatives and methods of use thereof
GT200500281A (es) * 2004-10-22 2006-04-24 Novartis Ag Compuestos organicos.
CA2585581A1 (en) * 2004-11-22 2006-05-26 King Pharmaceuticals Research & Development Inc. Enhancing treatment of hif-1 mediated disorders with adenosine a3 receptor agonists
GB0500785D0 (en) * 2005-01-14 2005-02-23 Novartis Ag Organic compounds
GB0514809D0 (en) 2005-07-19 2005-08-24 Glaxo Group Ltd Compounds
CA2627319A1 (en) 2005-11-30 2007-06-07 Prakash Jagtap Purine derivatives and methods of use thereof
GB0607953D0 (en) * 2006-04-21 2006-05-31 Novartis Ag Organic compounds
GB0607944D0 (en) * 2006-04-21 2006-05-31 Novartis Ag Organic compounds
KR20080110925A (ko) 2006-04-21 2008-12-19 노파르티스 아게 아데노신 ａ２ａ 수용체 효능제로서 사용하기 위한 퓨린 유도체
GB0607950D0 (en) 2006-04-21 2006-05-31 Novartis Ag Organic compounds
EP1889846A1 (de) 2006-07-13 2008-02-20 Novartis AG Purinderivate als A2a Agonisten
EP1903044A1 (de) 2006-09-14 2008-03-26 Novartis AG Adenosinderivate als Agonisten des A2A-Rezeptors
BRPI0718792A2 (pt) * 2006-11-10 2013-12-03 Novartis Ag Compostos orgânicos
ES2641190T3 (es) 2007-03-14 2017-11-08 Can-Fite Biopharma Ltd. Procedimiento de síntesis de IB-MECA
US20090088403A1 (en) * 2007-05-07 2009-04-02 Randy Blakely A3 adenosine receptors as targets for the modulation of central serotonergic signaling
DK2227234T3 (da) 2007-10-15 2014-08-11 Can Fite Biopharma Ltd Fremgangsmåde til induktion af hepatocytproliferering og anvendelserderaf
US9199102B2 (en) 2009-07-21 2015-12-01 Oradin Pharmaceutical Ltd. A3 adenosine receptor ligands for modulation of pigmentation
SG10201502588UA (en) 2010-01-11 2015-05-28 Inotek Pharmaceuticals Corp Combination, kit and method of reducing intraocular pressure
MX2012010724A (es) 2010-03-26 2012-11-12 Inotek Pharmaceuticals Corp Metodo para reducir la presion intraocular en seres humanos empleando n6-ciclopentiladenosina (cpa), derivados de cpa o profarmacos de los mismos.
US9073960B2 (en) 2011-12-22 2015-07-07 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
US20150018299A1 (en) * 2012-01-23 2015-01-15 Can-Fite Biopharma Ltd. Treatment of liver conditions
US9278991B2 (en) 2012-01-26 2016-03-08 Inotek Pharmaceuticals Corporation Anhydrous polymorphs of [(2R,3S,4R,5R)-5-(6-(cyclopentylamino)-9H-purin-9-yl)-3,4-dihydroxytetrahydrofuran-2-yl)} methyl nitrate and processes of preparation thereof
USRE48171E1 (en) 2012-03-21 2020-08-25 Janssen Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
US9441007B2 (en) 2012-03-21 2016-09-13 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
MX2015001644A (es) * 2012-08-09 2015-08-14 Can Fite Biopharma Ltd Ligandos del receptor de adenosina a3 para su uso en el tratamiento de una disfuncion sexual.
CN105188714A (zh) 2013-03-15 2015-12-23 伊诺泰克制药公司 眼用配制品
IL242723B (en) 2015-11-23 2019-12-31 Can Fite Biopharma Ltd A3 adenosine receptor ligand for the treatment of ectopic fat accumulation
WO2017185061A1 (en) 2016-04-21 2017-10-26 Astrocyte Pharmaceuticals, Inc. Compounds and methods for treating neurological and cardiovascular conditions
WO2019157317A1 (en) 2018-02-09 2019-08-15 Astrocyte Pharmaceuticals, Inc. Compounds and methods for treating addiction and related disorders
JP2022502405A (ja) 2018-09-26 2022-01-11 アストロサイト ファーマシューティカルズ， インコーポレイテッド 多形化合物およびその使用
IL272078A (en) 2020-01-16 2021-07-29 Can Fite Biopharma Ltd Cannabinoids for use in therapy

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5443836A (en) * 1993-03-15 1995-08-22 Gensia, Inc. Methods for protecting tissues and organs from ischemic damage
US5688774A (en) * 1993-07-13 1997-11-18 The United States Of America As Represented By The Department Of Health And Human Services A3 adenosine receptor agonists
EP0708781B1 (de) * 1993-07-13 2001-10-04 THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, Department of Health and Human Services A3 -adenosin -rezeptor agonisten
US6048865A (en) * 1997-07-29 2000-04-11 Medco Research, Inc. N6 -substituted-adenosine-5'-uronamides as adenosine receptor modulator
EP1019427A4 (de) 1997-07-29 2000-07-19 Medco Res Inc N6-substituierte adenosin-5'-uronamide als adenosin-rezeptor-modulatoren
WO1999020284A1 (en) 1997-10-23 1999-04-29 Trustees Of The University Of Pennsylvania Methods for reducing ischemic injury of the heart via the sequential administration of monophosphoryl lipid a and adenosine receptor agents
IL133680A0 (en) 1999-09-10 2001-04-30 Can Fite Technologies Ltd Pharmaceutical compositions comprising an adenosine receptor agonist or antagonist
US8076303B2 (en) * 2005-12-13 2011-12-13 Spring Bank Pharmaceuticals, Inc. Nucleotide and oligonucleotide prodrugs

Also Published As

Publication number Publication date
HK1064948A1 (en) 2005-02-08
EP1365776B1 (de) 2005-04-13
US20040106572A1 (en) 2004-06-03
BR0206492A (pt) 2004-02-10
JP2004517864A (ja) 2004-06-17
WO2002055085A2 (en) 2002-07-18
DE60203702D1 (de) 2005-05-19
CA2434906C (en) 2008-08-19
WO2002055085A3 (en) 2002-12-19
EP1365776A2 (de) 2003-12-03
AU2002219497B2 (en) 2004-08-26
CA2434906A1 (en) 2002-07-18
CN1489470A (zh) 2004-04-14
CN1259056C (zh) 2006-06-14
IL156704A0 (en) 2004-01-04
JP4012070B2 (ja) 2007-11-21
US7589075B2 (en) 2009-09-15
DE60203702T2 (de) 2006-03-02

Similar Documents

Publication Publication Date Title
DE60203702D1 (de) Verwendung eines adenosin-a3-rezeptor-agonisten zur hemmung der virenreplikation
Mizutani et al. Phosphorylation of p38 MAPK and its downstream targets in SARS coronavirus-infected cells
BR0206614A (pt) Composto, composição farmacêutica, método para inibir a polimerase viral de rna dependente de rna e/ou inibir a replicação viral de rna dependente de rna, método para tratar uma infecção viral de rna dependente de rna, e, uso de um composto
PA8484201A1 (es) Derivados de adenina
BRPI0415505A (pt) agente terapêutico para mesotelioma
UY26205A1 (es) Derivados de indoloxoacetil piperazina antiviricos
HK1091130A1 (en) Pharmaceuical compositions for hepatitis c viral protease inhibitors
HUP0300195A2 (hu) Heterociklusos nátrium/proton-csere inhibitorok és ezeket tartalmazó gyógyszerkészítmények
AU7788701A (en) System and method for optimizing tissue barrier transfer of compounds
ATE399847T1 (de) Reinigungsmittel vom typ der multiplen emulsion
HUP0303879A2 (hu) Zsíralkohol-etoxilátok alkalmazása penetrációt elősegítő szerként
DK0937074T3 (da) Benzonaphthyridiner som bronkiale terapeutiske midler
ES2147758T3 (es) Preparacion sinergistica para la activacion de celulas destructoras naturales.
WO2004085682A3 (de) Caspase inhibitoren, insbesondere von caspase-3, zur behandlung von influenza
BRPI0309651A2 (pt) método para prevenir ou reduzir a resistência a um pesticida de uma peste de substrato, composição de pesticida, uso dos mesmos, e, método para preparar uma composição de pesticida
DE69836678D1 (de) Chinolin- und chinazolinderivate als antagonisten des corticotropin freisetzenden faktors (crf)
ATE464878T1 (de) Pharmazeutische zusammensetzung zur nasalen anwendung von fentanyl
Yu et al. Osteoblast-like cells have a variable mixed population of purino/nucleotide receptors
Jashes et al. Inhibitors of infectious pancreatic necrosis virus (IPNV) replication
MXPA04004621A (es) Nucleotidos, preparaciones de los mismos y su utilizacion como inhibidores de polimerasas virales de arn.
ES2132383T3 (es) Inhibidores de proteasa hiv.
ATE356993T1 (de) Verfahren und industrieller prozess zur feststellung der dosierungspegeleigenschaften eines aus mehreren einheiten bestehenden systems
AU2003255611A1 (en) Novel antiretroviral sulpholipids extracted from spirulinae, method for obtaining same, compositions containing same and use thereof as inhibitors of the hiv virus reverse transcriptase
DK1331940T3 (da) Anvendelse af det lange pentraxin PTX3 til behandling af sygdomme forårsaget af ændret aktivering af vækstfaktoren FGF-2
ATE340567T1 (de) Transdermales therapeutisches system zur verabreichung des partiellen dopamin-d2-agonisten aripiprazol

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties